Mechanisms of action of bone morphogenetic proteins in cancer

Cytokine and Growth Factor Reviews

Volumn 27, Issue , 2016, Pages 81-92

  Davis, Hayley ^a   Raja, Erna ^b   Miyazono, Kohei ^b   Tsubakihara, Yutaro ^c,d   Moustakas, Aristidis ^d  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TOKYO   (Japan)

^c EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UPPSALA UNIVERSITY   (Sweden)

Author keywords

BMP; Cancer; EMT; Metastasis; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN; CHORDIN; NOGGIN; SMAD PROTEIN; TUMOR PROTEIN;

BRAIN TUMOR; BREAST CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL FATE; COLON CANCER; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE MUTATION; HUMAN; LIVER CANCER; MELANOMA SKIN CANCER; METASTASIS; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL SELF-RENEWAL; STOMACH CANCER; ANIMAL; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; BONE MORPHOGENETIC PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; SMAD PROTEINS;

EID: 84957426045     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.11.009     Document Type: Short Survey

References (135)

1. Reddi A.H. BMPs: from bone morphogenetic proteins to body morphogenetic proteins. Cytokine Growth Factor Rev. 2005, 16:249-250.
2. Ehata S., Yokoyama Y., Takahashi K., Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde?. Pathol. Int. 2013, 63:287-296.
3. Brazil D.P., Church R.H., Surae S., Godson C., Martin F. BMP signalling: agony and antagony in the family. Trends Cell. Biol. 2015, 25:249-264.
4. Nolan K., Thompson T.B. The DAN family: modulators of TGF-beta signaling and beyond. Protein Sci. 2014, 23:999-1012.
5. Davis H., Irshad S., Bansal M., et al. Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche. Nat. Med. 2015, 21:62-70.
6. Potti T.A., Petty E.M., Lesperance M.M. A comprehensive review of reported heritable noggin-associated syndromes and proposed clinical utility of one broadly inclusive diagnostic term: NOG-related-symphalangism spectrum disorder (NOG-SSD). Hum. Mutat. 2011, 32:877-886.
7. Akhurst R.J., Hata A. Targeting the TGF beta signalling pathway in disease. Nat. Rev. Drug Discov. 2012, 11:790-811.
8. Wakefield L.M., Hill C.S. Beyond TGFb: roles of other TGFb superfamily members in cancer. Nat. Rev. Cancer 2013, 13:328-341.
9. Ide H., Yoshida T., Matsumoto N., et al. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2. Cancer Res. 1997, 57:5022-5027.
10. Miyazaki H., Watabe T., Kitamura T., Miyazono K. BMP signals inhibit proliferation and in vivo tumor growth of androgen-insensitive prostate carcinoma cells. Oncogene 2004, 23:9326-9335.
11. Ghosh-Choudhury N., Ghosh-Choudhury G., Celeste A., et al. Bone morphogenetic protein-2 induces cyclin kinase inhibitor p21 and hypophosphorylation of retinoblastoma protein in estradiol-treated MCF-7 human breast cancer cells. Biochim. Biophys. Acta 2000, 1497:186-196.
12. WAF1,Cip1 during bone morphogenetic protein-induced growth arrest in human breast cancer cells. J. Endocrinol. 2002, 172:187-198.
13. WAF1/Cip1. J. Cell. Physiol. 2005, 204:260-272.
14. Qiu T., Grizzle W.E., Oelschlager D.K., Shen X., Cao X. Control of prostate cell growth: BMP antagonizes androgen mitogenic activity with incorporation of MAPK signals in Smad1. EMBO J. 2007, 26:346-357.
15. David L., Mallet C., Keramidas M., et al. Bone morphogenetic protein-9 is a circulating vascular quiescence factor. Circ. Res. 2008, 102:914-922.
16. Scharpfenecker M., van Dinther M., Liu Z., et al. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. J. Cell Sci. 2007, 120:964-972.
17. Suzuki Y., Montagne K., Nishihara A., Watabe T., Miyazono K. BMPs promote proliferation and migration of endothelial cells via stimulation of VEGF-A/VEGFR2 and angiopoietin-1/Tie2 signalling. J. Biochem. 2008, 143:199-206.
18. Suzuki Y., Ohga N., Morishita Y., Hida K., Miyazono K., Watabe T. BMP-9 induces proliferation of multiple types of endothelial cells in vitro and in vivo. J. Cell Sci. 2010, 123:1684-1692.
19. Gatza C.E., Elderbroom J.L., Oh S.Y., Starr M.D., Nixon A.B., Blobe G.C. The balance of cell surface and soluble type III TGF-beta receptor regulates BMP signaling in normal and cancerous mammary epithelial cells. Neoplasia 2014, 16:489-500.
20. Holtzhausen A., Golzio C., How T., et al. Novel bone morphogenetic protein signaling through Smad2 and Smad3 to regulate cancer progression and development. FASEB J. 2014, 28:1248-1267.
21. Ying Q.L., Nichols J., Chambers I., Smith A. BMP induction of Id proteins suppresses differentiation and sustains embryonic stem cell self-renewal in collaboration with STAT3. Cell 2003, 115:281-292.
22. Xu R.H., Peck R.M., Li D.S., Feng X., Ludwig T., Thomson J.A., Basic F.G.F. and suppression of BMP signaling sustain undifferentiated proliferation of human ES cells. Nat. Methods 2005, 2:185-190.
23. Li Z., Fei T., Zhang J., et al. BMP4 Signaling Acts via dual-specificity phosphatase 9 to control ERK activity in mouse embryonic stem cells. Cell. Stem Cell 2012, 10:171-182.
24. Kamiya D., Banno S., Sasai N., et al. Intrinsic transition of embryonic stem-cell differentiation into neural progenitors. Nature 2011, 470:503-509.
25. Wang Z., Oron E., Nelson B., Razis S., Ivanova N. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. Cell. Stem Cell 2012, 10:440-454.
26. Li Q., Gu X., Weng H., et al. Bone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci. 2013, 104:398-408.
27. Mizuseki K., Sakamoto T., Watanabe K., et al. Generation of neural crest-derived peripheral neurons and floor plate cells from mouse and primate embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:5828-5833.
28. Brown A.C., Muthukrishnan S.D., Oxburgh L. A synthetic niche for nephron progenitor cells. Dev. Cell 2015, 34:229-241.
29. Huang S.X., Islam M.N., O'Neill J., et al. Efficient generation of lung and airway epithelial cells from human pluripotent stem cells. Nat. Biotechnol. 2014, 32:84-91.
30. Iyer D., Gambardella L., Bernard W.G., et al. Robust derivation of epicardium and its differentiated smooth muscle cell progeny from human pluripotent stem cells. Development 2015, 142:1528-1541.
31. Alarmo E.L., Kuukasjarvi T., Karhu R., Kallioniemi A. A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Res. Treat. 2007, 103:239-246.
32. Rodriguez-Martinez A., Alarmo E.L., Saarinen L., et al. Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Med. Genom. 2011, 4:80.
33. Helms M.W., Packeisen J., August C., et al. First evidence supporting a potential role for the BMP/SMAD pathway in the progression of oestrogen receptor-positive breast cancer. J. Pathol. 2005, 206:366-376.
34. Pickup M.W., Hover L.D., Guo Y., et al. Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. Oncotarget 2015.
35. Kim I.Y., Lee D.H., Ahn H.J., et al. Expression of bone morphogenetic protein receptors type-IA, -IB and -II correlates with tumor grade in human prostate cancer tissues. Cancer Res. 2000, 60:2840-2844.
36. Yang S., Zhong C., Frenkel B., Reddi A.H., Roy-Burman P. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Res. 2005, 65:5769-5777.
37. Yang S., Pham L.K., Liao C.P., Frenkel B., Reddi A.H., Roy-Burman P. A novel bone morphogenetic protein signaling in heterotypic cell interactions in prostate cancer. Cancer Res. 2008, 68:198-205.
38. Nishimori H., Ehata S., Suzuki H.I., Katsuno Y., Miyazono K. Prostate cancer cells and bone stromal cells mutually interact with each other through bone morphogenetic protein-mediated signals. J. Biol. Chem. 2012, 287:20037-20046.
39. Feeley B.T., Krenek L., Liu N., et al. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 2006, 38:154-166.
40. Virtanen S., Alarmo E.L., Sandstrom S., Ampuja M., Kallioniemi A. Bone morphogenetic protein -4 and -5 in pancreatic cancer-novel bidirectional players. Exp. Cell Res. 2011, 317:2136-2146.
41. Voorneveld P.W., Stache V., Jacobs R.J., et al. Reduced expression of bone morphogenetic protein receptor IA in pancreatic cancer is associated with a poor prognosis. Br. J. Cancer 2013, 109:1805-1812.
42. Zhang L., Sun H., Zhao F., et al. BMP4 administration induces differentiation of CD133+ hepatic cancer stem cells, blocking their contributions to hepatocellular carcinoma. Cancer Res. 2012, 72:4276-4285.
43. Li L., Liu Y., Guo Y., et al. Regulatory MiR-148a-ACVR1/BMP circuit defines a cancer stem cell-like aggressive subtype of hepatocellular carcinoma. Hepatology 2015, 61:574-584.
44. Herrera B., Garcia-Alvaro M., Cruz S., et al. BMP9 is a proliferative and survival factor for human hepatocellular carcinoma cells. PLoS One 2013, 8:e69535.
45. Herrera B., van D., inther M., Ten D., ijke P., Inman G.J. Autocrine bone morphogenetic protein-9 signals through activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian cancer cell proliferation. Cancer Res. 2009, 69:9254-9262.
46. Hernanda P.Y., Chen K., Das A.M., et al. SMAD4 exerts a tumor-promoting role in hepatocellular carcinoma. Oncogene 2014.
47. Wen X.Z., Akiyama Y., Baylin S.B., Yuasa Y. Frequent epigenetic silencing of the bone morphogenetic protein 2 gene through methylation in gastric carcinomas. Oncogene 2006, 25:2666-2673.
48. Bleuming S.A., He X.C., Kodach L.L., et al. Bone morphogenetic protein signaling suppresses tumorigenesis at gastric epithelial transition zones in mice. Cancer Res. 2007, 67:8149-8155.
49. Shirai Y.T., Ehata S., Yashiro M., Yanagihara K., Hirakawa K., Miyazono K. Bone morphogenetic protein-2 and -4 play tumor suppressive roles in human diffuse-type gastric carcinoma. Am. J. Pathol. 2011, 179:2920-2930.
50. Scoville D.H., Sato T., He X.C., Li L. Current view: intestinal stem cells and signaling. Gastroenterology 2008, 134:849-864.
51. Kosinski C., Li V.S., Chan A.S., et al. Gene expression patterns of human colon tops and basal crypts and BMP antagonists as intestinal stem cell niche factors. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15418-15423.
52. Hardwick J.C., Kodach L.L., Offerhaus G.J., van, den B., rink G.R. Bone morphogenetic protein signalling in colorectal cancer. Nat. Rev. Cancer 2008, 8:806-812.
53. Jaeger E., Leedham S., Lewis A., et al. Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1. Nat. Genet. 2012, 44:699-703.
54. Tomlinson I.P., Carvajal-Carmona L.G., Dobbins S.E., et al. Multiple common susceptibility variants near BMP pathway loci GREM1, BMP4, and BMP2 explain part of the missing heritability of colorectal cancer. PLoS Genet. 2011, 7:e1002105.
55. Kodach L.L., Bleuming S.A., Musler A.R., et al. The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer. Cancer 2008, 112:300-306.
56. Kodach L.L., Wiercinska E., de Miranda N.F., et al. The bone morphogenetic protein pathway is inactivated in the majority of sporadic colorectal cancers. Gastroenterology 2008, 134:1332-1341.e3.
57. He X.C., Zhang J., Tong W.G., et al. BMP signaling inhibits intestinal stem cell self-renewal through suppression of Wnt-beta-catenin signaling. Nat. Genet. 2004, 36:1117-1121.
58. Kodach L.L., Jacobs R.J., Voorneveld P.W., et al. Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 2011, 60:1544-1553.
59. Lombardo Y., Scopelliti A., Cammareri P., et al. Bone morphogenetic protein 4 induces differentiation of colorectal cancer stem cells and increases their response to chemotherapy in mice. Gastroenterology 2011, 140:297-309.e6.
60. Deng H., Makizumi R., Ravikumar T.S., Dong H., Yang W., Yang W.L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp. Cell Res. 2007, 313:1033-1044.
61. Kang M.H., Kang H.N., Kim J.L., Kim J.S., Oh S.C., Yoo Y.A. Inhibition of PI3 kinase/Akt pathway is required for BMP2-induced EMT and invasion. Oncol. Rep. 2009, 22:525-534.
62. Kim B.R., Oh S.C., Lee D.H., et al. BMP-2 induces motility and invasiveness by promoting colon cancer stemness through STAT3 activation. Tumour Biol. 2015.
63. Lorente-Trigos A., Varnat F., Melotti A., Ruiz i Altaba A. BMP signaling promotes the growth of primary human colon carcinomas in vivo. J. Mol. Cell Biol. 2010, 2:318-332.
64. Voorneveld P.W., Kodach L.L., Jacobs R.J., et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br. J. Cancer 2015, 112:122-130.
65. Shi Y., Chen G.B., Huang X.X., et al. Dragon (repulsive guidance molecule b, RGMb) is a novel gene that promotes colorectal cancer growth. Oncotarget 2015.
66. Whissell G., Montagni E., Martinelli P., et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMP gene expression. Nat. Cell Biol. 2014, 16:695-707.
67. Beck S.E., Carethers J.M. BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol. Ther. 2007, 6:1313-1317.
68. Howe J.R., Roth S., Ringold J.C., et al. Mutations in the SMAD4/DPC4 gene in juvenile polyposis. Science 1998, 280:1086-1088.
69. Howe J.R., Sayed M.G., Ahmed A.F., et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J. Med. Genet. 2004, 41:484-491.
70. Batts L.E., Polk D.B., Dubois R.N., Kulessa H. Bmp signaling is required for intestinal growth and morphogenesis. Dev. Dyn. 2006, 235:1563-1570.
71. Haramis A.P., Begthel H., van den Born M., et al. De novo crypt formation and juvenile polyposis on BMP inhibition in mouse intestine. Science 2004, 303:1684-1686.
72. Beppu H., Mwizerwa O.N., Beppu Y., et al. Stromal inactivation of BMPRII leads to colorectal epithelial overgrowth and polyp formation. Oncogene 2008, 27:1063-1070.
73. Takaku K., Miyoshi H., Matsunaga A., Oshima M., Sasaki N., Taketo M.M. Gastric and duodenal polyps in Smad4 (Dpc4) knockout mice. Cancer Res. 1999, 59:6113-6117.
74. Taketo M.M., Takaku K. Gastro-intestinal tumorigenesis in Smad4 mutant mice. Cytokine Growth Factor Rev. 2000, 11:147-157.
75. Wach S., Schirmacher P., Protschka M., Blessing M. Overexpression of bone morphogenetic protein-6 (BMP-6) in murine epidermis suppresses skin tumor formation by induction of apoptosis and downregulation of fos/jun family members. Oncogene 2001, 20:7761-7769.
76. Rothhammer T., Poser I., Soncin F., Bataille F., Moser M., Bosserhoff A.K. Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration. Cancer Res. 2005, 65:448-456.
77. Sneddon J.B., Zhen H.H., Montgomery K., et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:14842-14847.
78. Hover L.D., Abel T.W., Owens P. Genomic Analysis of the BMP Family in Glioblastomas. Transl. Oncogenomics 2015, 7:1-9.
79. Buczkowicz P., Hoeman C., Rakopoulos P., et al. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet. 2014, 46:451-456.
80. Fontebasso A.M., Papillon-Cavanagh S., Schwartzentruber J., et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet. 2014, 46:462-466.
81. Taylor K.R., Mackay A., Truffaux N., et al. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet. 2014, 46:457-461.
82. Wu G., Diaz A.K., Paugh B.S., et al. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet. 2014, 46:444-450.
83. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
84. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
85. Bleau A.M., Hambardzumyan D., Ozawa T., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell. Stem Cell 2009, 4:226-235.
86. Alcantara Llaguno S., Chen J., Kwon C.H., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 2009, 15:45-56.
87. Chen J., Li Y., Yu T.S., et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
88. Holland E.C., Celestino J., Dai C., Schaefer L., Sawaya R.E., Fuller G.N. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat. Genet. 2000, 25:55-57.
89. Alcantara Llaguno S.R., Chen Y., McKay R.M., Parada L.F. Stem cells in brain tumor development. Curr. Top. Dev. Biol. 2011, 94:15-44.
90. Piccirillo S.G., Reynolds B.A., Zanetti N., et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006, 444:761-765.
91. Tate C.M., Pallini R., Ricci-Vitiani L., et al. A BMP7 variant inhibits the tumorigenic potential of glioblastoma stem-like cells. Cell Death Differ. 2012, 19:1644-1654.
92. Savary K., Caglayan D., Caja L., et al. Snail depletes the tumorigenic potential of glioblastoma. Oncogene 2013, 32:5409-5420.
93. Lee J., Son M.J., Woolard K., et al. Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell 2008, 13:69-80.
94. Yan K., Wu Q., Yan D.H., et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014, 28:1085-1100.
95. Guo M., Jiang Z., Zhang X., et al. miR-656 inhibits glioma tumorigenesis through repression of BMPR1A. Carcinogenesis 2014, 35:1698-1706.
96. Bao Z., Zhang C., Yan W., et al. BMP4, a strong better prognosis predictor, has a subtype preference and cell development association in gliomas. J. Transl. Med. 2013, 11:100.
97. Videla R., ichardson G.A., Garcia C.P., Roisman A., et al. Specific preferences in lineage choice and phenotypic plasticity of glioma stem cells under BMP4 and Noggin influence. Brain Pathol. 2015.
98. Srikanth M., Kim J., Das S., Kessler J.A. BMP signaling induces astrocytic differentiation of clinically derived oligodendroglioma propagating cells. Mol. Cancer Res. 2014, 12:283-294.
99. Alvarez-Rodriguez R., Barzi M., Berenguer J., Pons S. Bone morphogenetic protein 2 opposes Shh-mediated proliferation in cerebellar granule cells through a TIEG-1-based regulation of Nmyc. J. Biol. Chem. 2007, 282:37170-37180.
100. Zhao H., Ayrault O., Zindy F., Kim J.H., Roussel M.F. Post-transcriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev. 2008, 22:722-727.
101. Fiaschetti G., Castelletti D., Zoller S., et al. Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma. Oncogene 2011, 30:2823-2835.
102. Jones C., Baker S.J. Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat. Rev. Cancer 2014, 14.
103. Tan E.J., Olsson A.K., Moustakas A. Reprogramming during epithelial to mesenchymal transition under the control of TGFbeta. Cell Adh. Migr. 2015, 9:233-246.
104. Buijs J.T., Henriquez N.V., van O., verveld P.G., et al. Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res. 2007, 67:8742-8751.
105. Buijs J.T., der H., orst G., den H., oogen C., et al. The BMP2/7 heterodimer inhibits the human breast cancer stem cell subpopulation and bone metastases formation. Oncogene 2012, 31:2164-2174.
106. Kobayashi A., Okuda H., Xing F., et al. Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone. J. Exp. Med. 2011, 208:2641-2655.
107. Yang S., Du J., Wang Z., et al. BMP-6 promotes E-cadherin expression through repressing deltaEF1 in breast cancer cells. BMC Cancer 2007, 7:211.
108. Mock K., Preca B.T., Brummer T., Brabletz S., Stemmler M.P., Brabletz T. The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget 2015, 6:14399-14412.
109. Tarragona M., Pavlovic M., Arnal-Estape A., et al. Identification of NOG as a specific breast cancer bone metastasis-supporting gene. J. Biol. Chem. 2012, 287:21346-21355.
110. Gao H., Chakraborty G., Lee-Lim A.P., et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012, 150:764-779.
111. Pangas S.A., Li X., Umans L., et al. Conditional deletion of Smad1 and Smad5 in somatic cells of male and female gonads leads to metastatic tumor development in mice. Mol. Cell Biol. 2008, 28:248-257.
112. Katsuno Y., Hanyu A., Kanda H., et al. Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 2008, 27:6322-6333.
113. Balboni A.L., Hutchinson J.A., DeCastro A.J., et al. DeltaNp63alpha-mediated activation of bone morphogenetic protein signaling governs stem cell activity and plasticity in normal and malignant mammary epithelial cells. Cancer Res. 2013, 73:1020-1030.
114. Sakai H., Furihata M., Matsuda C., et al. Augmented autocrine bone morphogenic protein (BMP) 7 signaling increases the metastatic potential of mouse breast cancer cells. Clin. Exp. Metastasis 2012, 29:327-338.
115. Dai J., Keller J., Zhang J., Lu Y., Yao Z., Keller E.T. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res. 2005, 65:8274-8285.
116. Lee Y.C., Cheng C.J., Bilen M.A., et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res. 2011, 71:5194-5203.
117. Buijs J.T., Rentsch C.A., van der Horst G., et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am. J. Pathol. 2007, 171:1047-1057.
118. Pickup M.W., Hover L.D., Polikowsky E.R., et al. BMPR2 loss in fibroblasts promotes mammary carcinoma metastasis via increased inflammation. Mol. Oncol. 2015, 9:179-191.
119. Owens P., Polikowsky H., Pickup M.W., et al. Bone Morphogenetic Proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion. PLoS One 2013, 8:e67533.
120. Lee J.H., Lee G.T., Woo S.H., et al. BMP-6 in renal cell carcinoma promotes tumor proliferation through IL-10-dependent M2 polarization of tumor-associated macrophages. Cancer Res. 2013, 73:3604-3614.
121. Raida M., Clement J.H., Leek R.D., et al. Bone morphogenetic protein 2 (BMP-2) and induction of tumor angiogenesis. J. Cancer Res. Clin. Oncol. 2005, 131:741-750.
122. Xiao F., Qiu H., Cui H., et al. MicroRNA-885-3p inhibits the growth of HT-29 colon cancer cell xenografts by disrupting angiogenesis via targeting BMPR1A and blocking BMP/Smad/Id1 signaling. Oncogene 2015, 34:1968-1978.
123. Yoshimatsu Y., Lee Y.G., Akatsu Y., et al. Bone morphogenetic protein-9 inhibits lymphatic vessel formation via activin receptor-like kinase 1 during development and cancer progression. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:18940-18945.
124. Cunha S.I., Bocci M., Lovrot J., et al. Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer. Cancer Res. 2015, 75:2445-2456.
125. Caja L., Bellomo C., Moustakas A. Transforming growth factor beta and bone morphogenetic protein actions in brain tumors. FEBS Lett. 2015, 589:1588-1597.
126. Chirasani S.R., Sternjak A., Wend P., et al. Bone morphogenetic protein-7 release from endogenous neural precursor cells suppresses the tumourigenicity of stem-like glioblastoma cells. Brain 2010, 133:1961-1972.
127. Owens P., Pickup M.W., Novitskiy S.V., et al. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 2015, 34:2437-2449.
128. Hover L.D., Young C.D., Bhola N.E., et al. Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth. Cancer Lett. 2015.
129. Wang Z., Shen Z., Li Z., et al. Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:9990-9995.
130. Cunha S.I., Pardali E., Thorikay M., et al. Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. J. Exp. Med. 2010, 207:85-100.
131. Hu-Lowe D.D., Chen E., Zhang L., et al. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Cancer Res. 2011, 71:1362-1373.
132. Cao Y., Wang C., Zhang X., et al. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Sci. Rep. 2014, 4(4965).
133. Duggal R., Geissinger U., Zhang Q., et al. Vaccinia virus expressing bone morphogenetic protein-4 in novel glioblastoma orthotopic models facilitates enhanced tumor regression and long-term survival. J. Transl. Med. 2013, 11:155.
134. Reguera-Nunez E., Roca C., Hardy E., de la Fuente M., Csaba N., Garcia-Fuentes M. Implantable controlled release devices for BMP-7 delivery and suppression of glioblastoma initiating cells. Biomaterials 2014, 35:2859-2867.
135. Persano L., Pistollato F., Rampazzo E., et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis. 2012, 3:e412.